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Special delivery: microRNA-200-containing extracellular vesicles provide metastatic message to distal tumor cells David 
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Promoting metastasis: microRNA-200 family members and extracellular vesicles
Considering the large number of tumor cells that are estimated to be released daily into the circulation of cancer patients, metastasis and distal colonization is a relatively rare event (1). In this issue, Le and colleagues (2) provide new insight into potential mechanisms that regulate multiple steps of the metastatic process via the intercellular transmission of nucleic acids and proteins packaged within tumor cell-secreted extracellular vesicles (EVs). In an elegant series of experiments, Le and colleagues expand on initial observations that correlate metastatic properties of isogenic mouse breast cancer cell lines (4T1 and 4T07) to the intrinsic expression of miR-200 family microRNAs (3). Lieberman and colleagues previously demonstrated that the strongly metastatic cells could confer metastasis-associated properties upon otherwise nonmetastatic cells through ectopic expression of miR-200 microRNAs (3). This observation furthered the general understanding that miR-200 microRNAs control both the epithelial phenotype (via epithelial-mesenchymal transition) and metastatic properties of tumor cells (4-6). In their current report, Le and colleagues analyze a series of physiologically relevant studies demonstrating that EVs secreted from metastatic breast tumor cells contain a blueprint of prometastatic regulatory cargo that is apparently distinct from that within EVs of nonmetastatic cells. Quite simply, the results of this study indicate that the metastatic potential of an otherwise nonmetastatic tumor cell can be increased through exposure to and uptake of cargo encapsulated in EVs from a metastatic soul mate.
Le and colleagues compared EVs derived from a metastatic murine cancer cell line (4T1E) and a nonmetastatic murine cancer cell line (4TO7). 4T1E cells are an epithelial variant with high E-cadherin expression that uniformly metastasizes to the lungs, while 4TO7 cells are nonmetastatic in murine models. Both cell lines produced EVs of similar size and distribution (50-310 nm), indicating exosome and ectosome secretion. Particles that were enriched for the EV markers TSG101 and ALIX also contained AGO2, a protein associated with mature miRNAs. Importantly, members of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-429, miR-141 , collectively referred to as miR-200s) were elevated in metastatic 4T1E cell-derived EVs compared with EVs derived from nonmetastatic 4TO7 cells. Extracellular miRNAs were encapsulated within an intact vesicle, as miR-200s in culture supernatants were only sensitive to RNAse treatment in the presence of membrane-solubilizing agents. Furthermore, the level of miR-200s in EVs paralleled their relative abundance in the host cell, suggesting that these microRNAs are not specifically selected for packaging during EV biogenesis: therefore, the EV-associated miR-200 fingerprint is the same in both the vesicle and the host tumor cell. This observation has important implications for the development of therapeutics and biomarkers for breast cancer (7). Future work should expand our understanding of whether specific miRNAs are targeted to EVs or whether the miRNAs within EVs are simply an inherent product of the host tumor cell miRNA transcriptome.
The observation by Le et al. that tumor cell-derived EVs carry the miRNA fingerprint and prometastatic code of the donor cell conjoins earlier observations that EVRelated Article: p. 5109
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The author has declared that no conflict of interest exists. An emerging view is that breast cancer is a systemic disease that utilizes intrinsic and extrinsic tumor cell processes to support both primary tumor growth and metastatic dissemination into distal tissue. Delineation of factors involved in these processes should facilitate a better understanding for both assessing and preventing disease relapse. In this issue of the JCI, Le et al. investigate whether intrinsic properties of metastatic breast cancer cell growth can be regulated through an extrinsic process -contact with tumor cell-derived extracellular vesicles containing microRNAs of the miR-200 family. The authors provide compelling evidence that miR-200s within extracellular vesicles secreted from highly metastatic tumor cells can be internalized by weakly metastatic cells. Thus, internalization and delivery of this metastatic "donor" cell-derived message provide plausible mechanisms by which oncogenic and regulatory factors confer the capability of tumor growth at metastatic lesions. This study provides a strong rationale for detailed assessment of the prognostic and predictive value of circulating extracellular vesicle-bound miR-200s in breast cancer progression and treatment.
The 
Conclusions and future direction
The current study by Le and colleagues provides compelling evidence that the heterogeneous tumor environment may contain "donor" metastatic cell populations that confer metastatic capacity to weakly metastatic "recipient" tumor cells. 
EV and miR-200 function in vivo
Circulating EVs and miRNAs have been identified in the serum of cancer patients (9, 12), yet the physiological relevance of tumor-derived EVs in disease progression has remained unresolved. Le and colleagues provide compelling experimental support for the idea that miR-200-expressing donor cells promote the growth of neighboring nonmetastatic tumor cells in murine cancer and human xenograft models. Specifically, mice bearing mixed tumors comprising differentially labeled metastatic and nonmetastatic cells exhibited metastasis of both populations, while animals implanted with only
